%0 Journal Article
%T Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries.
%A Rolland B
%A Matheson C
%A Kaski A
%A Kosim M
%A Roncero C
%A Vorspan F
%J Expert Opin Drug Deliv
%V 21
%N 5
%D 2024 May 19
%M 38898689
%F 8.129
%R 10.1080/17425247.2024.2369756
%X <B>UNASSIGNED: </B>Buvidal is the only depot buprenorphine currently available in Europe. Buvidal offers a new treatment paradigm, which may require some adjustment in the national regulatory frameworks for opioid agonist treatments (OATs), as well as the national care systems.<BR><B>UNASSIGNED: </B>Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.<BR><B>UNASSIGNED: </B>In 2022, the proportion of people on OAT who received Buvidal was 2.1% in the UK, 60-65% in Finland, 1% in Spain, and 0.3% in France. In both Finland and the UK, the cost of the medication is covered by the national health system, whereas, in Spain and France, Buvidal is accessible only in specialized centers, which must carry its cost. Other national features may explain the gaps in Buvidal use, including the baseline level of OAT coverage, which was high in both France and Spain.<BR><B>UNASSIGNED: </B>Important national discrepancies are found regarding Buvidal dissemination among people on OAT.